Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge

NCT00889473 is registered in ClinicalTrials.gov with 9 Meters Biopharma, Inc. as lead sponsor.

NCT NCT00889473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00889473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge
Lead sponsor
9 Meters Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
April 30, 2010
Enrollment
42 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease